Search results for "COPD"
Metoprolol not effective for reducing time to COPD exacerbation
A randomized placebo-controlled trial, which was stopped early due to safety and futility concerns, found no significant between-group difference in median time to first exacerbation of chronic obstructive pulmonary disease (COPD).
https://immattersacp.org/weekly/archives/2019/10/29/4.htm
29 Oct 2019
‘Year of the Lung’ draws attention to COPD, asthma
Chronic respiratory disease is projected to be the third most common cause of death by 2020, but it currently underestimated. This year's American Thoracic Society meeting focuses on issues to bring them to the attention of the rest of the medical community.
https://immattersacp.org/archives/2010/07/thoracic-copd.htm
1 Jul 2010
MKSAP Quiz: Posthospital evaluation for severe COPD
A 64-year-old woman is evaluated during a posthospital visit for severe COPD with an FEV1 of 30% of predicted. She has been admitted three times during the last year with acute exacerbations. Following physical and pulmonary exams, what is the most appropriate treatment to reduce this patient's COPD exacerbations?
https://immattersacp.org/weekly/archives/2019/08/20/3.htm
20 Aug 2019
New COPD treatment, warnings on insomnia and migraine drugs
This regulatory update covers approval of a combined long-term maintenance treatment for chronic obstructive pulmonary disease, warnings against driving after taking insomnia drugs and on use of migraine drugs in pregnant women, and more.
https://immattersacp.org/archives/2013/07/fda.htm
1 Jul 2013
New questionnaire appears to successfully identify COPD in primary care settings
A survey, combined with selective peak expiratory flow, was the best method for predicting undiagnosed, clinically significant chronic obstructive pulmonary disease, a recent case-control study found.
https://immattersacp.org/weekly/archives/2016/11/08/5.htm
8 Nov 2016
Triple inhaler therapy associated with reduced COPD exacerbations, higher rates of pneumonia
Results of the systematic review and meta-analysis suggest that triple inhaler therapy should be limited to patients with more severe symptoms of chronic obstructive pulmonary disease (COPD) that cannot be adequately managed by dual therapy, the authors said.
https://immattersacp.org/weekly/archives/2018/11/13/2.htm
13 Nov 2018
New diabetes drug, LABA for COPD, skin antibiotic approved
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a new intravenous drug for bacterial skin and skin-structure infections.
https://immattersacp.org/archives/2014/10/fda.htm
1 Oct 2014
Guidance on using rapid tests, managing COPD, and screening for cardiac problems in COVID-19
The FDA warned about false positives with rapid tests, guidance addressed care for chronic obstructive pulmonary disease (COPD) during the pandemic, and experts advised on ethics of emergency use authorizations, among other recent COVID-19 news.
https://immattersacp.org/weekly/archives/2020/11/10/1.htm
10 Nov 2020
Task Force recommends against screening for COPD
The recommendation applies to asymptomatic adults, defined as those who do not recognize or report respiratory symptoms.
https://immattersacp.org/weekly/archives/2016/04/12/4.htm
12 Apr 2016
New drugs approved for type 2 diabetes and COPD
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
https://immattersacp.org/archives/2014/03/fda.htm
1 Mar 2014